FDA: Draft Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products

This draft guidance is intended to assist manufacturers and clinical investigators involved in the development of therapeutic protein products for human use. In this document, FDA outlines and recommends adoption of a risk-based approach to evaluating and mitigating immune responses to therapeutic proteins that may adversely affect their safety and efficacy.